key: cord-1029724-licg7tyu authors: Zavattaro, Elisa; Cammarata, Edoardo; Tarantino, Vanessa; Soddu, Daniele; Gironi, Laura C.; Savoia, Paola title: Successful treatment of a bullous vasculitis with intravenous immunoglobulins in a COVID‐19 patient date: 2021-02-18 journal: Dermatol Ther DOI: 10.1111/dth.14853 sha: 72faa544108265c21c160790d078b29d4ae4650f doc_id: 1029724 cord_uid: licg7tyu nan cal history included ischemic heart disease, congestive heart failure and hyperuricemia, chronically treated with diuretics, acetylsalicylic acid, anti-hypertensives, and allopurinol. Even if an iatrogenic origin of the vasculitis was firstly suspected, due to the onset of slight dyspnea, fever, and blood test abnormalities (lymphocytopenia, neutrophilia), the patient was tested positive for SARS-CoV-2. Chest computed tomography (CT) revealed the presence of bilateral, central and peripheral ground glass opacities; because of the appearance of dyspnea, he required oxygen therapy via nasal cannula. He did not complain of any other COVID-19 symptoms. The patient's skin condition rapidly deteriorated, with the extension of the lesions beyond the lower limbs ( Figure 1B ) and despite the prompt treatment with prednisone 1 mg/kg/d, and the suspension of the potentially involved drugs, lesions progressed with the development of multiple necrotic areas in few days. Given the laboratory tests negativity (Table 1 ) and the absence of response to the steroid therapy, the diagnosis was directed toward viral vasculitis. Based on this suspicion, steroid therapy was rapidly tapered, and treatment with high-dose IVIG (2 g/kg, that is, 400 mg/kg/daily for five consecutive days) was started, together with low-molecular weight heparin, with a rapid improvement of the lung symptoms, and a slight benefit to the cutaneous lesions in 7 days. One month later, the ulcerative and escharotic lesions were completely demarcated with initial reepithelization ( Figure 1C ). Unfortunately, the patient died a few weeks later due to a further hearth failure episode. The novel COVID-19 infection may affect various organs, thus leading to multiple and heterogeneous clinical features. Also, cutaneous manifestations have been described with erythematous rash, widespread urticaria, acroischemia, and, more rarely, vasculitis. 2 Accordingly, a small case series of COVID-19 patients presenting acroischemic lesions associated with the presence of antiphospholipid antibodies has been recently reported. 3 Following the recent attempts F I G U R E 1 (A) Purpuric macules and papules involving lower extremities, with bullae and initial aspects of central ulceration and necrosis; (B) Extension of the lesions beyond the lower limbs, with diffuse necrotic aspects; (C) Clinical feature 1 month after the disease onset of classification of cutaneous lesions SARS-CoV-2-related, the present case reports of "livedoid/necrotic lesions" that should be enclosed in the purpuric "vasculitic" pattern. 4, 5 IVIG are currently used in autoimmune diseases resistant to other treatment, thus including vasculitis. Moreover, on the basis of their previous favorable experiences from patients with SARS and MERS, 6, 7 IVIG has also been suggested against COVID-19. The rationale for their use is due, given the presence of autoreactive antibodies, to the ability to reduce the inflammatory status, thus promoting the early recovery. Moreover, IVIG therapy has been recently reported to be of help to mitigate the SARS-CoV-2 infection symptoms in a patient complaining of mucosal pemphigoid. 8 Accordingly, IVIG represent the pivotal treatment in Kawasaki disease, whose increased frequency has been recently correlated to COVID-19 infection. In our case, we cannot affirm that the cutaneous lesions were virus-related, but, on the basis of the existing literature, we could speculate it. Hence, the association between Coronavirus and cutaneous vasculitis has been previously reported, either in human or in veterinary field. 9,10 Accordingly, the detection of autoantibodies against human epithelial and endothelial cell lines has been previously demonstrated in patients affected by SARSassociated Coronavirus infection. 11 Regarding COVID-19, the presence of endothelial damage and endotheliitis virus-related has been recently demonstrated in patients, and this represents a further support to the previously suggested role of the SARS-CoV-2 promoting hypercoagulopathy. 12, 13 However, it can be speculated that the same mechanism could be involved in our patient, thus provoking a COVID-19-mediated vasculitis. Furthermore, the concomitant appearance of cutaneous lesions in the course of COVID-19 represents another clue toward such conclusion. Moreover, the plethora of papers reporting vascular damages provoked by SARS-CoV-2, seems to support such hypothesis. An unusual case of bullous hemorrhagic vasculitis in a COVID-19 patient Cutaneous signs in COVID-19 patients: a review Coagulopathy and antiphospholipid antibodies in patients with Covid19 Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375cases Skin manifestations associated with COVID-19: current knowledge and future perspectives Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection Mucous membrane pemphigoid and COVID-19 treated with highdose intravenous immunoglobulins: a case-report Acute hemorrhagic edema of infancy after coronavirus infection with recurrent rash. Case Rep Pediatr Cutaneous lesions associated with coronavirus-induced vasculitis in a cat with feline infectious peritonitis and concurrent feline immunodeficiency virus infection Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection Endothelial cell infection and endotheliitis in COVID-19 SARS-CoV-2 and coagulation disorderd in different organs